Ipilimumab vs Trastuzumab
Ipilimumab vs Trastuzumab: Overview
This comparison examines the pharmacological differences between Ipilimumab and Trastuzumab.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Trastuzumab — 28 days.
Chemical Properties
Type: Ipilimumab — Antibody; Trastuzumab — Antibody.